Basal Cell Carcinoma Pipeline Landscape Examined by GMD in In-demand Research Study Published at MarketPublishers.com
06 Jun 2017 • by Natalie Aster
LONDON – Basal cell carcinoma (BCC) is a form of cancer that starts in the skin’s basal cells that line the outmost layer of the epidermis. Amid the major symptoms one can name waxy bump, brown, scaly, or flesh-coloured patch and waxy, white scar. BCC is primarily caused by an amalgamation of cumulative and excessive, random exposure to UV rays from the sun or from a sun tanning bed. Other predisposing factors comprise age, family history, and immunosuppressants. Treatment options comprise chemotherapy and surgical operation.
Over 4 million basal cell carcinoma cases are diagnosed in the USA annually. More than 1 out of every 3 novel cancers is a skin cancer, and the extensive majority belongs within BCCs.
In-demand research report “Basal Cell Carcinoma - Pipeline Review, H1 2017” drawn up by Grace Market Data (GMD) is devoted to examining the BCC pipeline universe.
The publication provides an all-round review of the worldwide therapeutic landscape of BCC; gives an overview of pipeline therapeutic agents for BCC broken down by firms and universities/research organisations. The report provides information on pipeline products on the basis of various phases of development. The study casts light on the drug profiles for the products in pipeline, which enclose product description, descriptive details about licensing and collaboration, R&D brief, MoA & other related activities. The research reviews top companies engaged in BCC therapeutics, alongside enlisting all their key and minor projects. It evaluates BCC therapeutics based on MoA, drug target, RoA and molecule type. Insights into discontinued and dormant pipeline projects are also provided. The report also sheds light on the latest news pertaining to the pipeline therapeutics for BCC.
To find more insightful market research studies drawn up by GMD, follow to its page at MarketPublishers.com.